Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University, Gutenbergstr. 76-78, Kiel, Germany.
J Enzyme Inhib Med Chem. 2012 Feb;27(1):24-8. doi: 10.3109/14756366.2011.573480. Epub 2011 Jul 8.
DDAH inhibition presents a novel promising pharmaceutical strategy to lower NO formation. To date, several potent DDAH inhibitors have been published, most of them representing analogues of l-arginine. While inhibitory effects on NOSs have already been considered, selectivity over arginase has been neglected so far. In our view, the latter selectivity is more important since an additional inhibition of arginase decreases the desired effects on NO levels. Thus, we particularly focus on selectivity over arginase. We present a comprehensive selectivity profile of known DDAH inhibitors by covering their inhibitory potency on arginase. Among the studied compounds, N(ω)-(2-methoxyethyl)-l-arginine (2a, L-257) that is already selective over NOSs also only modestly affected arginase activity and is thus far the most suitable DDAH inhibitor for pharmacological studies.
DDAH 抑制为降低 NO 形成提供了一种新的有前景的药物策略。迄今为止,已经发表了几种有效的 DDAH 抑制剂,其中大多数是 l-精氨酸的类似物。虽然已经考虑了对 NOS 的抑制作用,但到目前为止,对精氨酸酶的选择性还被忽视了。在我们看来,后者的选择性更为重要,因为精氨酸酶的额外抑制会降低对 NO 水平的预期效果。因此,我们特别关注对精氨酸酶的选择性。我们通过涵盖它们对精氨酸酶的抑制效力来呈现已知 DDAH 抑制剂的综合选择性概况。在所研究的化合物中,N(ω)-(2-甲氧基乙基)-l-精氨酸(2a,L-257)已经对 NOS 具有选择性,对精氨酸酶活性的影响也不大,因此它是目前最适合药理学研究的 DDAH 抑制剂。